UroGen Pharma is a clinical-stage biopharmaceutical company developing advanced, minimally invasive treatments to address unmet needs in the field of urology, with a focus on uro-oncology.
We have developed RTGel ™, a novel drug delivery technology platform, that is liquid when chilled, but gels at body temperature. We believe RTGel technology has the potential to be applied to a variety of unmet medical needs where increased exposure to the active drug would improve the therapeutic profile of existing drugs while decreasing toxicity associated with systemic delivery, making local therapy a potentially more effective treatment option. Our investigational RTGel-based drug formulations are designed to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer.
Our lead investigational product candidates, UGN-101 (mitomycin gel) for upper tract instillation and UGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially chemoablate tumors and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and bladder cancer, respectively. We believe that UGN-101 and UGN-102 may have the potential to significantly improve patients’ quality of life by potentially replacing costly, sub-optimal and burdensome tumor resection and kidney removal surgeries as the first-line standard of care.
UroGen is committed to changing the treatment paradigm for patients suffering from urologic cancers and other urological conditions. With our team, our partners and our novel RTGel drug delivery system technology platform, we are developing new and innovative, minimally invasive therapies that have the potential to change the standard of care across multiple indications.
UroGen has over 60 patents and patent applications with 11 patents granted in the U.S. and 15 patents granted in other jurisdictions.
The Company is headquartered in New York, NY with operations in Los Angeles, CA and Israel.
The Company’s clinical stage pipeline also includes a proprietary immunotherapy investigational product candidate for the treatment of carcinoma in situ of the bladder using a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7/8, or TLR 7/8, agonist.
In addition, in October 2016 UroGen granted an exclusive worldwide license to Allergan to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel technology and clostridial toxins, including onabotulinumtoxin A. Allergan is presently conducting a Phase II clinical trial of RTGel in combination with BOTOX ® (onabotulinumtoxin A) for the treatment of overactive bladder.
*BOTOX is a registered trademark of Allergan Pharmaceuticals
RTGel technology is not commercially available. The safety and efficacy of investigational drugs that contain RTGel technology has not been established.
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001